$GBT $ACAD $MDCO $XBI $CRSP .. The Biotech Analyst Run Down For Tuesday https://seekingalpha.com/instablog/498952-bret-jensen/5379227-biotech-analyst-run-tuesday Next up is Acadia Pharmaceuticals (ACAD). The midcap biopharma is getting plenty of praise from analysts today after posting the latest trial results for its flagship product Nuplazid yesterday. Four analyst firms including Needham and Cowen & Co. have reissued Buy ratings. Price targets range from $57 to $66 a share. The stock has almost quadrupled since a CNN story around Nuplazid's safety helped pushed the shares down into the $12 range in the second quarter of last year. Fortunately for shareholders, that just turned out to be some 'fake news' from the much maligned network. CNN FAKE news when $12 !